ThermoGenesis (THMO) 10-K2017 FY Annual report

Filed: 22 Sep 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accompanyingconsolidated, Accurate, afer, affiliate, affiliated, agent, Agreementwith, alliance, andWe, aregenerative, articular, assist, attestation, attorney, auditor, AutoXpress®platform, bankruptcy, Basedon, Bay, biobanking, Bruch, bulk, cartilage, cartilageregeneration, Cauble, Chinese, circulation, Clara, clarification, CMC, CODM, COMMONEQUITY, compensatory, conclusion, consolidatedfinancial, COO, County, customary, cv, CXP, defense, degeneration, deliveringhigh, DISCUSSIONAND, Distinguishing, division, downstream, dramatically, drawn, drew, encompassing, endedJune, endovascular, ERP, expandingthe, expended, filewithin, foregoing, forstem, froman, fromthe, fulfill, fullsuite, headcount, Hedging, hereof, immune, inselected, Jeff, joint, jointly, killer, Lender, Liu, Loan, Mahendra, Maker, Mandatorily, manner, maximum, medicinecompany, mentioned, Michael, Narrow, NK, noncash, Noncontrolling, Nonpublic, OA, ofautomated, ofJune, output, Payor, penalty, pioneer, pool, PotentialCell, promissory, promote, proprietaryPXP™platform, providesa, PXP, PXP™system, Rao, ratifying, Redeemable, RELATIONSHIPSAND, relieved, retrospectiveapproach, Revolving, Santa, signature, solution, stimulate, strike, supermajority, surgery, surrender, tender, therapiesat, therewith, thevascular, thirty, toEnter, top, true, unqualified, unsecured, virtue, Vivian, yearsended

Removed: adjustment, afflicted, AMI, AMIRST, announced, applying, artery, assembled, automatic, batch, bedside, BioParadox, BMT, cardiac, catheterization, Celling, combined, consistent, Depleting, deprived, direction, donation, earlier, ejection, elimination, equitable, extension, family, generation, goal, hindsight, hybrid, installed, ischemic, Japan, leg, licensee, meeting, minimize, module, mononuclear, MXP, nonfinancial, noted, NYBC, opening, optimal, optimization, optimized, owner, preceding, President, prevention, produced, PRP, pursuing, recognizing, regained, Registry, renewal, reperfusion, reviewing, salvage, satisfaction, serving, sharing, simplify, Sivilotti, smart, sourced, streamline, targeted, targeting, team, threatening, transfusion, ulceration, validate, visible, vision, VXP

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

THMO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Cesca Therapeutics Inc. (the “Company”) on Form 10-K for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.


	Dated: September 21, 2017	/s/Chris Xu
		Chris Xu Chief Executive Officer


	Dated: September 21, 2017	/s/ Jeff Cauble
		Jeff Cauble Principal Financial and Accounting Officer